A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain
The purpose of this trial is to test the safety and tolerance of the combination therapy with cytarabine, lomustine and radiotherapy in patients with leptomeningeal metastasis from malignant melanoma.
Leptomeningeal Metastasis From Malignant Melanoma
RADIATION: Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|DRUG: Lomustine|DRUG: Liposomal cytarabine
Safety/Tolerance, The primary endpoint is safety and tolerance and will be based on the frequency and severity of adverse events., 30 weeks
Delay of treatments, Frequency and median time of delay of each of the treatments (lomustine, liposomal cytarabine, radiotherapy)., 30 weeks|Response rate, Overall response rate determined by clinical, MRI- and CSF-cytological assessment criteria., 30 weeks|Progression, Neurological progression, progression free survival, overall survival., 30 weeks
The purpose of this trial is to test the safety and tolerance of the combination therapy with cytarabine, lomustine and radiotherapy in patients with leptomeningeal metastasis from malignant melanoma.